Next-Generation Sequencing-based, Tumor- and Plasma-informed Droplet Digital PCR Assay for Detection of Circulating Tumor DNA in Peripheral T-cell Lymphomas
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
The aim of this study is to evaluate the feasibility of circulating tumor DNA (ctDNA) measurement in blood plasma for the applicability in prognostication, treatment evaluation and measurable residual disease (MRD) surveillance in a cohort of patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphomas (PTCL).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphoma.
• All primary systemic PTCL entities from the International Consensus Classification 2022.
• ≥18 years of age.
• Life expectancy of 3 months or longer.
• ECOG performance status 0-4 at study entry (PS4 only if lymphoma-induced).
• Measurable disease.
• Written informed consent.
Locations
Other Locations
Denmark
Department of Hematology, Aarhus University Hospital
RECRUITING
Aarhus
Contact Information
Primary
Patrick R Noerhave, MD
panoer@rm.dk
+4551543715
Time Frame
Start Date: 2024-03-01
Estimated Completion Date: 2030-12
Participants
Target number of participants: 50
Related Therapeutic Areas
Sponsors
Leads: University of Aarhus
Collaborators: Aarhus University Hospital